Clinical Trial

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
▪ Fulvestrant With Ribociclib versus Physician's choice treatments for the patients who recurred after completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer as first line treatment
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-23; most recent amendment 2025-12-17.
Trial Details
NCT Number NCT06849947
Lead Sponsor Yeon Hee Park
Conditions Breast Cancer Metastatic
Enrollment 272 participants
Start Date 2026-02-01
Primary Completion 2031-06-30 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-24